IDEX Corporation

Notable Price Movement

After Hours
Apr 30
$217.85
0.23%
IDEX Corporation is trading modestly lower today, consolidating after surging to a new 52-week high yesterday following a blowout Q1 2026 earnings report. The company posted adjusted EPS of $2.00, handily beating estimates of $1.77, on revenue of $886.9 million that topped consensus by roughly $40 million — representing 9% year-over-year growth driven by 5% organic growth and record orders of $988.3 million. Management raised full-year 2026 adjusted EPS guidance to $8.35–$8.55 (above prior $8.15–$8.35), with the HST segment — fueled by AI data center and semiconductor demand — posting 17% sales growth. Today, multiple analysts have raised price targets in response, including RBC Capital (to $252), Citigroup (to $252), Baird (to $257), Oppenheimer (to $242), and BMO Capital (to $230), reflecting broad confidence in IDEX's growth trajectory across its industrial end markets.

Apr 29
$217.34
5.83%
IDEX Corporation surged after delivering a blowout Q1 2026 earnings report, with adjusted EPS of $2.00 beating the $1.77 consensus by $0.23 and revenue of $886.9M topping estimates by over $40M — up 9% year-over-year. Record orders of $988M (up 13%) and 17% sales growth in the Health & Science Technologies segment, driven by AI data center and semiconductor demand, fueled investor enthusiasm. Management raised full-year 2026 adjusted EPS guidance to $8.35–$8.55 from $8.15–$8.35, above consensus, and lifted organic sales growth guidance to 3–4% from 1–2%, pushing shares to a new 52-week high and outperforming the industrials sector (XLI).

Apr 28
$205.36
0.98%
IDEX Corporation edged lower, underperforming the broader industrials sector (XLI closed flat) amid a risk-off session driven by AI growth concerns and surging oil prices above $110/barrel tied to Middle East tensions. Investor focus is squarely on Wednesday's Q1 2026 earnings report, with analysts carrying a 'Moderate Buy' consensus and an average price target of $228.90—well above current levels. Stifel recently trimmed its target to $241 but maintained a 'buy,' while the company has guided Q1 EPS of $1.73–$1.78 and FY2026 EPS of $8.15–$8.35 following a Q4 beat.

Key Issues
Sustainability of Health & Science Technologies (HST) growth and AI/data center demand

Bullish view

IDEX's HST segment is delivering exceptional momentum, with management forecasting high single-digit growth driven by data center, semiconductor, and space and defense applications. CEO Eric Ashleman highlighted robust order activity and strong backlog visibility, with Q1 2026 revenue beating estimates by 4.7% and orders growing 10% year-over-year organically.

Bearish view

Despite the near-term HST tailwinds, trailing EPS growth over five years has been only 2.3% annually, casting doubt on whether the forecasted 14.7% annual earnings growth is achievable. Volume softness in semiconductors and agriculture, combined with exposure to cyclical end markets, may undermine sustained HST-driven outperformance.

Symbol
IEX
IPO Date
Jun 1, 1989
CEO
Eric D. Ashleman
Fulltime Employees
9K
Sector
Industrials
Industry
Industrial - Machinery
Country
United States